drugset / Trial / NCT04530357

Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine

NCT04530357 ↗

RandomizedParallel-groupSingle-blindPrevention

Summary

Randomized, blind, placebo-controlled phase- i study and randomized, open phase phase-ii study of QAZCOVID-IN®- COVID-19 inactivated vaccine in healthy adult volunteers from 18 years old and elder

Timeline

Start
2020-09-19
Primary completion
2020-11-25
Completion
2021-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject QazCovid-in® Vaccine 0.5 ml Intramuscular

Indications